Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary
Compounding Law; Health Care; Awareness of all Types of Compounding Issues;
Pharmacy Benefit Managers (PBMs), Outsourcing Facilities
Food and Drug Administration and Compliance Issues
Saturday, August 24, 2013
Study will track long-term effects of meningitis outbreak from compounding nightmare
Federal regulators have launched a study of the long-term health effects of a lethal fungalmeningitis outbreaklast fall linked to tainted steroids from a Framingham pharmacy.
The federal Centers for Disease Control and Prevention said Friday that it would fund a $216,000 study led by Dr. Peter Pappas, an infectious disease specialist at the University of Alabama School of Medicine, who leads a nationwide consortium of scientists who specialize in fungal infections.
Pappas’s team will track 500 patients from the states hardest hit in the outbreak — Indiana, Michigan, Tennessee, and Virginia — said Dr. Mary Brandt, who leads the CDC’s fungal diseases branch.
Overall, the CDC says medications from the New England Compounding Center of Framingham are believed to have sickened 749 people, including 63 who have since died.